Related Experiment Video
Updated: May 12, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Rhabdomyolysis developing secondary to atorvastatin therapy in a patient with liver cirrhosis
Ahad Eshraghian1, Amir A'lam Kamyab
1Department of Internal Medicine, Shiraz University of Medical Sciences, Iran. Eshraghiana@yahoo.com
Abstract:
Atorvastatin is a lipid lowering agent that is widely used worldwide. Rhabdomyolysis is a rare but serious side effect that may lead to renal failure and dangerous electrolyte abnormalities in patients with decreased hepatic clearance of atorvastatin. We herein report the case of a patient with liver cirrhosis receiving atorvastatin therapy for ischemic heart disease and hyperlipidemia who developed rhabdomyolysis and acute renal failure.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cirrhosis II: Pathophysiology
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Cirrhosis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment